Trexquant Investment LP Purchases 177,342 Shares of AtriCure, Inc. $ATRC

Key Points

• Trexquant Investment LP significantly increased its stake in AtriCure, Inc. by 180.6% during Q1, holding 275,548 shares worth approximately $8.89 million.
• Multiple investors have recently adjusted their positions in AtriCure, with institutional ownership currently at 99.11% of the stock.
• AtriCure's latest earnings report showed an increase in revenue of 17.1% year-over-year, beating consensus estimates with revenue of $136.14 million for the quarter.

Trexquant Investment LP increased its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 180.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 275,548 shares of the medical device company's stock after buying an additional 177,342 shares during the period. Trexquant Investment LP owned about 0.56% of AtriCure worth $8,889,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. increased its position in AtriCure by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 4,714,371 shares of the medical device company's stock valued at $152,086,000 after acquiring an additional 61,166 shares during the period. Neuberger Berman Group LLC grew its position in shares of AtriCure by 26.3% in the first quarter. Neuberger Berman Group LLC now owns 1,186,065 shares of the medical device company's stock valued at $38,365,000 after purchasing an additional 246,877 shares during the last quarter. Nuveen LLC purchased a new stake in shares of AtriCure in the first quarter valued at $30,666,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of AtriCure by 24.5% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 747,806 shares of the medical device company's stock valued at $24,124,000 after buying an additional 147,000 shares during the period. Finally, Wellington Management Group LLP boosted its holdings in shares of AtriCure by 7.3% during the first quarter. Wellington Management Group LLP now owns 702,055 shares of the medical device company's stock worth $22,648,000 after purchasing an additional 47,551 shares during the last quarter. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

AtriCure Stock Up 2.1%

Shares of AtriCure stock traded up $0.75 during midday trading on Thursday, reaching $35.52. 56,529 shares of the company's stock traded hands, compared to its average volume of 571,653. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -46.21 and a beta of 1.62. The company's 50 day simple moving average is $33.83 and its 200 day simple moving average is $33.69. AtriCure, Inc. has a 52 week low of $25.50 and a 52 week high of $43.11. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.83 and a current ratio of 3.94.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The medical device company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.13. The company had revenue of $136.14 million for the quarter, compared to analyst estimates of $130.17 million. AtriCure had a negative net margin of 7.27% and a negative return on equity of 4.20%. The company's quarterly revenue was up 17.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.17) earnings per share. AtriCure has set its FY 2025 guidance at -0.390--0.340 EPS. Equities analysts expect that AtriCure, Inc. will post -0.6 earnings per share for the current fiscal year.

Insider Transactions at AtriCure

In other AtriCure news, Director Regina E. Groves sold 2,452 shares of the company's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $36.82, for a total transaction of $90,282.64. Following the transaction, the director owned 33,715 shares of the company's stock, valued at approximately $1,241,386.30. This represents a 6.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Vinayak Doraiswamy sold 2,500 shares of AtriCure stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $36.58, for a total value of $91,450.00. Following the completion of the sale, the insider directly owned 71,872 shares of the company's stock, valued at $2,629,077.76. This trade represents a 3.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,952 shares of company stock valued at $546,733. 3.50% of the stock is owned by insiders.

Analyst Ratings Changes

ATRC has been the topic of a number of research analyst reports. Wall Street Zen upgraded AtriCure from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Needham & Company LLC raised their price target on shares of AtriCure from $44.00 to $45.00 and gave the stock a "buy" rating in a research report on Wednesday, July 30th. Finally, BTIG Research set a $54.00 target price on AtriCure in a research report on Wednesday, July 30th. Nine research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $50.89.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.